Cargando…
Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID‐19 epidemic
Since its outbreak in December 2019 in China, the novel coronavirus disease (COVID‐19) has rapidly spread and affected several countries. It has resulted in a difficult situation for cancer patients owing to the risks of the epidemic situation outbreak as well as cancer. Patients with cancer are mor...
Autores principales: | Zhao, Zhe, Bai, Hua, Duan, Jianchun, Wang, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262202/ https://www.ncbi.nlm.nih.gov/pubmed/32291968 http://dx.doi.org/10.1111/1759-7714.13424 |
Ejemplares similares
-
Clinical recommendations for perioperative immunotherapy‐induced adverse events in patients with non‐small cell lung cancer
por: Ni, Jun, et al.
Publicado: (2021) -
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
por: Zhuang, Junling, et al.
Publicado: (2020) -
Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events
por: Zheng, Ke, et al.
Publicado: (2020) -
Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019) -
Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)